AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
desoxycortone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| corticosteroids, except prednisolone derivatives | 820 | 64-85-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | O |
| 5 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.562 | Moderate | 0.73 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.647 | Moderate | 0.73 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 69.343 | 10^-6 cm/s | Moderate | 0.73 |
| dh-clint | Dog hepatocyte intrinsic clearance | 32.961 | uL/min/10^6 cells | Moderate | 0.73 |
| dppb | Dog plasma protein binding (% unbound) | 11.370 | % | Moderate | 0.73 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 15.790 | % | Moderate | 0.73 |
| herg | hERG pIC50 | 4.557 | pIC50 | Moderate | 0.73 |
| hh-clint | Human hepatocyte intrinsic clearance | 11.995 | uL/min/10^6 cells | Moderate | 0.73 |
| hlm-clint | Human liver microsomal intrinsic clearance | 42.462 | uL/min/mg protein | Moderate | 0.73 |
| hppb | Human plasma protein binding (% unbound) | 8.340 | % | Moderate | 0.73 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,NTRK2,PDK1,PDK2,PDK4,PRKDC | 14 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.540 | Moderate | 0.67 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.560 | Moderate | 0.73 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 184.927 | Moderate | 0.73 | |
| mppb | Mouse plasma protein binding (% unbound) | 13.250 | Moderate | 0.73 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 3.846 | Moderate | 0.73 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 18.260 | % | Moderate | 0.73 |
| rat-kpuu-brain | Rat brain Kpuu | 0.627 | % | Moderate | 0.67 |
| rh-clint | Rat hepatocyte intrinsic clearance | 218.776 | uL/min/10^6 cells | Moderate | 0.73 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 65.890 | % | Moderate | 0.73 |
| rppb | Rat plasma protein binding (% unbound) | 15.490 | % | Moderate | 0.73 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 154.525 | uM | Moderate | 0.73 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H02AA03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CORTICOSTEROIDS FOR SYSTEMIC USE CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN Mineralocorticoids |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D008901 | Mineralocorticoids |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Related Drugs by ATC class:
H02AA Mineralocorticoids 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.85 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mineralocorticoid receptor | Nuclear hormone receptor | AGONIST | IC50 | 11 | IUPHAR | CHEMBL | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.50 | PDSP | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 8.70 | PDSP | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 8.85 | PDSP | |||||
| Corticosteroid-binding globulin | Secreted | Ki | 7.65 | CHEMBL | |||||
| Sex hormone-binding globulin | Secreted | Kd | 7.38 | CHEMBL | |||||
| Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | IC50 | 7.20 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4019710 | VUID |
| N0000147802 | NUI |
| D07792 | KEGG_DRUG |
| 3256 | RXNORM |
| 4019710 | VANDF |
| C0011710 | UMLSCUI |
| CHEBI:16973 | CHEBI |
| 1CA | PDB_CHEM_ID |
| CHEMBL1200542 | ChEMBL_ID |
| CHEMBL1498 | ChEMBL_ID |
| DB15972 | DRUGBANK_ID |
| 387 | INN_ID |
| 40GP35YQ49 | UNII |
| 6166 | PUBCHEM_CID |
| 002207 | NDDF |
| 1336006 | SNOMEDCT_US |
| 75029008 | SNOMEDCT_US |
| D003900 | MESH_DESCRIPTOR_UI |
| 2871 | IUPHAR_LIGAND_ID |
| 40GP35YQ49 | INXIGHT DRUGS |
Pharmaceutical products:
None